{"organizations": [], "uuid": "2b140146575fdcb698eb5533066e186a591395d4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180522.html", "section_title": "Archive News &amp; Video for Tuesday, 22 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sanofi-says-fda-to-review-zynquist/brief-sanofi-says-fda-to-review-zynquista-as-potential-treatment-for-type-1-diabetes-idUSFWN1ST0DL", "country": "US", "domain_rank": 408, "title": "BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.962, "site_type": "news", "published": "2018-05-22T20:59:00.000+03:00", "replies_count": 0, "uuid": "2b140146575fdcb698eb5533066e186a591395d4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sanofi-says-fda-to-review-zynquist/brief-sanofi-says-fda-to-review-zynquista-as-potential-treatment-for-type-1-diabetes-idUSFWN1ST0DL", "ord_in_thread": 0, "title": "BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sanofi sa", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 22 (Reuters) - Sanofi SA:\n* FDA TO REVIEW ZYNQUISTAâ„¢ (SOTAGLIFLOZIN) AS POTENTIAL TREATMENT FOR TYPE 1 DIABETES\n* SANOFI - TARGET FDA ACTION DATE UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA) IS ANTICIPATED TO BE MARCH 22, 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T20:59:00.000+03:00", "crawled": "2018-05-23T15:23:05.045+03:00", "highlightTitle": ""}